Live
- Meet Kannada Actor Tarak Ponnappa, Who Steals the Show in Pushpa 2: The Rule
- Union Minister Rajnath Singh to Attend Bhakti TV’s Koti Deepotsavam in Hyderabad
- MakeMyTrip Will Acquire CRED's Happay Expense Management Platform to Improve its Business Travel Services
- TTD Board Makes Path-Breaking Decisions
- BRS Social Media In-charge Dilip Arrested for Provocative Posts
- Andhra Pradesh Assembly Approves Seven Major Bills
- Odisha BJP leader Samir Dey passes away
- Average grievance redressal time reduced to 13 days from 30 days: Centre
- Average grievance redressal time reduced to 13 days from 30 days: Centre
- Maharashtra all set for MahaYuti vs MVA contest as high-octane campaigning ends
Dr Reddy’s out licenses steroid DFD-06 to Encore
Highlights
Drug major Dr Reddy’s Laboratories (DRL) has out-licensed the future development, manufacturing and commercialisation rights of its topical high potency steroid DFD-06 to Encore Dermatology. The drug is used for treatment of moderate to severe plaque psoriasis.
Hyderabad: Drug major Dr Reddy’s Laboratories (DRL) has out-licensed the future development, manufacturing and commercialisation rights of its topical high potency steroid DFD-06 to Encore Dermatology. The drug is used for treatment of moderate to severe plaque psoriasis.
Dr Reddy’s Laboratories in a communique to BSE said: “Under the terms of agreement, Encore will be responsible for the commercialisation of DFD-05 in the United States.” Promius Pharma, a wholly-owned subsidiary of Dr Reddy’s, is eligible to receive certain pre and post commercialisation milestone payments of up to $32.5 million, followed by fixed royalty.
Next Story
ADVERTISEMENT
